OncoMatch/Clinical Trials/NCT02919644
Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Is NCT02919644 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including autologous dendritic cells loaded with autologous tumour homogenate and IL2 for stage iv colorectal cancer.
Treatment: autologous dendritic cells loaded with autologous tumour homogenate · IL2 — Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgery — curative resection for stage IV colorectal cancer
surgically treated with radical intent
Cannot have received: preoperatory chemotherapy with a fluoropyrimidine plus oxaliplatin
Exception: unless not candidate for postoperatory chemotherapy with the same schedule (e.g. for unacceptable toxicity) or refuse completion of the perioperatory treatment
Patients undergone surgery after preoperatory chemotherapy with a fluoropyrimidine plus oxaliplatin, unless they are not candidate for postoperatory chemotherapy with the same schedule in the opinion of the Investigator (e.g. for unacceptable toxicity) or refuse completion of the perioperatory treatment
Lab requirements
Blood counts
haemoglobin >10 g/dl; white blood cells ≥4000/μl; absolute neutrophil count >1500/μl; platelets ≥100000/μl
Kidney function
serum creatinine <1.5 times the upper institutional reference level
Liver function
ast and alt <3 times the upper institutional reference level; total bilirubin <1.5 times the upper institutional reference level
Cardiac function
patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02919644 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior preoperatory chemotherapy with a fluoropyrimidine plus oxaliplatin disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages